P/E ratio for Redhill Biopharma (RDHL)

P/E ratio history for Redhill Biopharma from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Sanofi SNY	13.2	-769,858.91%	🇫🇷 France
Merck MRK	13.3	-775,108.90%	🇺🇸 USA
GlaxoSmithKline GSK	13.5	-788,000.53%	🇬🇧 UK
Taro Pharmaceutical TARO	70.4	-4,109,241.39%	🇮🇱 Israel
Teva Pharmaceutical Industries TEVA	45.1	-2,630,646.76%	🇮🇱 Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.